AT&T Expands Fiber Reach with $5.75 Billion Lumen Acquisition

Published 1 hours agoT

AT&T Expands Fiber Reach with $5.75 Billion Lumen Acquisition

AT&T is making significant strides in expanding its fiber internet infrastructure by acquiring Lumen Technologies' consumer fiber business for $5.75 billion. The deal will add around 1 million fiber internet customers to AT&T’s portfolio. This expansion will enhance its presence in key cities, including Denver, Las Vegas, and Seattle, marking a considerable boost to its existing network.

According to Reuters, this acquisition supports AT&T's strategic focus on doubling its fiber internet footprint to approximately 60 million locations by the end of 2030. The transaction is anticipated to conclude in the first half of 2026, marking a vital step in AT&T's ongoing efforts to accelerate its fiber network expansion.

With the sale, Lumen aims to use the proceeds to decrease its debt by $4.8 billion. The company plans to pivot towards its enterprise fiber sectors and develop technology segments that support AI and multi-cloud workflows. Market reactions were positive, as Lumen's shares saw a 13% increase in after-market trading following the announcement.

Share this article

Twitter Facebook LinkedIn

Recent Articles

CPS Technologies Reaches Record 52-Week High Amid Strong Performance

CPS Technologies Reaches Record 52-Week High Amid Strong Performance

6 minutes agoCPSH

CPS Technologies Corporation has achieved a new 52-week high with its stock reaching $2.48 per share. This milestone comes following significant growth and key achievements, including record revenue and profitability in recent quarters. Reuters highlighted that the company reached an intraday high of $2.68, reflecting robust trading activity and investor interest. The company posted a record $7.5 million in revenue for Q1 2025, marking a 27% increase from the previous year. This surge was fueled by strong demand for its AlSiC and hermetic packaging products. Notably, CPS Technologies also returned to profitability with a net income of $0.1 million, overturning a net loss from the same period in 2024. Additionally, operational improvements led to a gross margin of 16.4%, up from 15.3% a year earlier. Strategic initiatives were also bolstered by securing three new Phase I Army SBIR contracts. CPS Technologies' diversified growth strategy has yielded impressive results, as evidenced by its Q1 performance which included record revenue achieved without contributions from its HybridTech Armor® business. These strategic moves and financial improvements demonstrate the company's resilience and adaptability in a competitive market, supporting its recent uptick in stock performance.

FDA Approves GSK's Nucala for COPD Treatment

FDA Approves GSK's Nucala for COPD Treatment

21 minutes agoGSK

GlaxoSmithKline (GSK) has announced that the U.S. Food and Drug Administration (FDA) granted approval for its drug, Nucala, to be used in treating chronic obstructive pulmonary disease (COPD), also known as 'smoker's lung.' This new approval allows Nucala to be used specifically as an add-on treatment for COPD patients who have an eosinophilic phenotype, characterized by elevated eosinophil levels, which can lead to increased lung inflammation. The approval follows promising results from the MATINEE Phase 3 trial, which showed that adding Nucala to standard inhaled maintenance therapy significantly reduced the annualized rate of moderate or severe exacerbations in patients compared to a placebo over a period of up to 104 weeks. According to Reuters, such advances are substantial considering that approximately 300 million people worldwide are affected by COPD, with an estimated 40% of these cases involving type 2 inflammation. In the competitive landscape, other treatments for COPD include Dupixent from Sanofi and Regeneron, and Ohtuvayre from Verona Pharma. Financially, Nucala has been a strong performer for GSK, with sales growing 18% to reach £1.7 billion in 2023, making up nearly 6% of the company's total sales. This approval is expected to further enhance GSK's position in the COPD market.

Bruker Corp's Stock Slightly Dips Amid Revised Price Targets

Bruker Corp's Stock Slightly Dips Amid Revised Price Targets

36 minutes agoBRKR

As of May 22, 2025, Bruker Corporation's stock is trading at $36.29, experiencing a modest decrease of 0.44% from the previous day's close. The stock opened at $35.79 and saw an intraday high of $36.51 and a low of $35.54, with a trading volume of 1,257,779 shares by the latest trade time at 19:01:06 UTC. Citigroup recently adjusted its outlook on Bruker, reducing the price target from $75.00 to $50.00 while keeping a "Buy" rating, according to marketbeat.com. This revision highlights concerns over potential order fluctuations, particularly in China, which accounts for about 14% of Bruker's sales. However, this hasn't dampened all investor sentiment as other analysts remain optimistic. Bank of America increased its price target for Bruker from $78.00 to $80.00, maintaining a "Buy" rating. Similarly, Citi reaffirmed its "Buy" rating with a price target of $80.00, citing strong revenue guidance and growth potential. Despite some apprehension regarding order volatility, the company remains an attractive prospect for those banking on its growth strategies.

Ralph Lauren Eyes Price Hikes to Tackle Tariff Pressures

Ralph Lauren Eyes Price Hikes to Tackle Tariff Pressures

51 minutes agoRL

Ralph Lauren is contemplating raising prices to offset the impact of tariffs affecting its sales forecast. The company has projected low single-digit growth for fiscal 2026, citing challenges like tariffs, inflation, and weak consumer sentiment as major hurdles, according to Reuters. CEO Patrice Louvet outlined plans for further price increases in 2025 and spring 2026. These moves aim to address evolving tariffs and build on existing pricing strategies already implemented in North America and Asia. With about 96% of Ralph Lauren's products manufactured outside the U.S. and 12% sourced from China, diversifying the supply chain is pivotal to mitigating tariff risks. Despite a recent cut in U.S. tariffs on Chinese goods from 145% to 30%, this reduction might be temporary, posing potential risks to revenue growth. Analysts still expect a 4.39% revenue rise, but ongoing trade tensions could influence Ralph Lauren's allure in international markets, particularly in China.